Explore Typewriter Therapeutics careers and hiring status. Find jobs at Typewriter Therapeutics and official application links when roles are open. Funding stage: Series A. Headcount: 11-50. Typewriter Therapeutics develops RNA-based, non-viral gene insertion medicines using its Target-Primed Reverse Transcription (TPRT) platform built on the R2 retrotransposon system. The company is pursuing durable, re-dosable gene therapies including in vivo CAR-T for cancer, autoimmune, and severe genetic diseases, with operations in Cambridge, Massachusetts and Tokyo.
This page summarizes open roles, company profile signals, and official application paths so candidates can quickly evaluate fit before applying. Use the role list below to identify team focus, review location patterns, and jump to source listings. For broader comparison across the market, continue to the full company directory and jobs explorer.
Typewriter Therapeutics is a Series A stage AI startup, founded in 2022, with $56M in total disclosed funding. Its most recent round was a $56M Series A in Sep 2026. It has no open roles listed at the moment; new Typewriter Therapeutics openings are tracked daily. Source: Fast AI Jobs company dataset, updated Sep 2026.
Company profile last updated on Sep 5, 2026.
Typewriter Therapeutics careers and hiring status: no open roles are currently listed here, but you can review the company profile and check the official career page for the latest openings. Official careers page
Typewriter Therapeutics is an biotech company. Typewriter Therapeutics develops RNA-based, non-viral gene insertion medicines using its Target-Primed Reverse Transcription (TPRT) platform built on the R2 retrotransposon system. The company is pursuing durable, re-dosable gene therapies including in vivo CAR-T for cancer, autoimmune, and severe genetic diseases, with operations in Cambridge, Massachusetts and Tokyo.
Open positions
Check the official career page, browse adjacent companies, or subscribe for new openings.
Candidate questions
Typewriter Therapeutics develops RNA-based, non-viral gene insertion medicines using its Target-Primed Reverse Transcription (TPRT) platform built on the R2 retrotransposon system. The company is pursuing durable, re-dosable gene therapies including in vivo CAR-T for cancer, autoimmune, and severe genetic diseases, with operations in Cambridge, Massachusetts and Tokyo.
Typewriter Therapeutics does not have open roles listed on our platform right now. Visit the official company website or career page for the latest openings, or subscribe to get notified when new roles are posted.
Typewriter Therapeutics has raised $56M in total. The latest known stage is Series A.
Typewriter Therapeutics reports an employee count of 11-50.
Typewriter Therapeutics was founded in 2022.
Typewriter Therapeutics is associated with Biotech, Healthcare.
Company context
Typewriter Therapeutics is a Series A stage AI startup, founded in 2022, with $56M in total disclosed funding. Its most recent round was a $56M Series A in Sep 2026. It has no open roles listed at the moment; new Typewriter Therapeutics openings are tracked daily. Source: Fast AI Jobs company dataset, updated Sep 2026.